Claims
- 1. A method for producing a compound suitable for in vitro or in vivo usage as a diagnostic, therapeutic or prophylactic agent that possesses a complementary structure to a desired molecule or portion thereof comprising the following steps:
(i) selecting a particular molecule to which a compound having a complementary structure is to be produced; (ii) contacting such molecule with one or more complementary monomers under conditions wherein such monomers associate around one or more residues of such molecule; (iii) effecting polymerization of such associated monomers optionally in the presence of at least one crosslinking agent to produce a polymeric coating that is comprised on the surface of said molecule and which possesses a complementary structure to said molecule or a portion thereof; (iv) removing said molecule under conditions that result in a polymeric compound that possesses a complementary structure to said molecule or portion thereof; and (v) optionally effecting one or more cleavage and/or dissociation steps to produce compounds that are suitable for in vivo usage as a diagnostic, therapeutic and/or prophylactic agent.
- 2. The method of claim 1, wherein said molecule is immobilized to a support.
- 3. The method of claim 1, wherein said molecule is a biomolecule and is selected from the group consisting of a protein, a nucleic acid sequence, a carbohydrate, a peptide, a glycoprotein, a cell, a virus, a pathogen, and a tissue.
- 4. The method of claim 3, wherein said protein is selected from the group consisting of an enzyme, antigen, antibody, hormone, receptor, and a fragment thereof.
- 5. The method of claim 1, wherein the crosslinking agent comprises at least one cleavable crosslinker.
- 6. The method of claim 5, wherein said crosslinker is selected from the group consisting of bis-acrylcystamine, N,N-diallyltartardiamide, N,N-(1,2-dihydroxyethylen) bisacrylamide, or N,N′-bis-(acryloyl)cystomine, N1-(CE)-1-(4-vinylphenyl)methylidene)-4-vinyl aniline, allyl disulfide, bis(2-(methacyl, 1-oxyethyl)) disulfide.
- 7. A method of using the compound in vivo produced according to claim 1 as a therapeutic or diagnostic agent comprising administering to a subject in need of such treatment a therapeutically or diagnostically effective amount of said compound.
- 8. The method according to claim 1, wherein the molecule to which a compound having a complementary structure is to be produced is insoluble.
- 9. The method of claim 8, wherein said molecule is an enzyme crystal or a crosslinked enzyme.
- 10. An improved method of affinity purification which purifies a compound using a compound that specifically binds thereto, wherein the improvement comprising using a compound produced according to claim 1 to effect purification.
- 11. An improved assay method which includes the use of a competitive affinity ligand wherein the improvement comprises using as the competitive affinity ligand a compound produced according to claim 1.
- 12. The method of claim 1, wherein the compound produced by said method is suitable for use as an active agent selected from the group consisting of a hormone, enzyme, or receptor antagonist or agonist; gene expression modulator, antimicrobial agent, and an anti-tumor agent.
- 13. The method of claim 1, wherein the compound which results from said method is subsequently attached to a therapeutic or diagnostic agent.
- 13. A method for producing a polymeric compound that exhibits complementary structure to a microbial or mammalian cell comprising the following steps:
(i) immobilizing a microbial or mammalian cell to a support; (ii) coating said support and immobilized microbial or mammalian cell with a polymer that is crosslinkable under specific conditions; (iii) selectively crosslinking the portion of the molecular coating that is proximate to the immobilized mammalian or microbial cell; and (iv) removing the resultant molecular coating from the microbial or mammalian cell.
- 15. The method of claim 14, wherein the polymer is a photocrosslinkable polymer.
- 16. The method of claim 15, wherein the polymers areas not proximate to the immobilized microbial or mammalian cell are covered with a photomask during photocrosslinking.
- 17. The method of claim 14, wherein the support is a thin layer support.
- 18. The method of claim 14, wherein the polymer coating in step (ii) is introduced by a method selected from the group consisting of spray-coating, dip-coating, and spin-coating.
- 19. The method of claim 14, wherein the resultant polymeric coating is suitable for use as a cell separating material.
- 20. The method of claim 14,wherein the molecular coating is subsequently cleaved into oligomers which function as anti-microbial agents.
- 21. A method for producing a compound that has a complementary structure to the active site of a desired molecule comprising the following steps:
(i) providing a support which is coated with a first monomer layer coating; (ii) applying to said first monolayer a second layer which comprises at least one crosslinkable monomer which is able to move freely in said second layer; (iii) exposing said second layer to a molecule containing at least one active site and allowing for said crosslinkable monomer to associate around said at least one active site; (iv) providing a crosslinking agent and effecting crosslinking to produce a crosslinked compound that possesses a complementary structure to said at least one active site; and (v) recovering said crosslinked compound that possesses a complementary structure to said at least one active site or sites.
- 22. The method of claim 21, wherein said molecule is an enzyme or a receptor.
- 23. The method of claim 22, wherein the resultant polymeric compound functions as an antagonist or agonist.
- 24. A method for producing a polymeric or oligomeric compounds that has a complementary structure to a desired molecule comprises the following steps:
(i) providing a preformed functionalized polymer that is linear or lightly crosslinked and contacting same with a desired molecular entity such that specific functional groups on the polymer interact covalently or non-covalently with specific residues on the molecular entity; (ii) allowing for such non-covalent or covalent interactions between the functional groups on the polymer and the molecular entity to equilibrate; (iii) subjecting the resultant equilibrated covalent or complex non-covalent between the polymer and the molecular entity be at least one of the following steps:
(1) chemically treating the functional groups on the polymer that interact least strongly with the molecular entity by site-selective chemical modification; (2) chemically treating the functional groups on the polymer that interact most strongly with the molecular entity by site-selective chemical modification; and (3) crosslinking the polymer; (iv) separating the molecular entity from the resultant polymer.
- 25. The method of claim 24, wherein the molecular entity is in solution or immobilized to a support.
- 26. The method of claim 24, wherein crosslinking is effected using a reversible cleavable crosslinking agent.
- 27. A compound produced according to claim 1.
- 28. A compound produced according to claim 14.
- 29. A compound produced according to claim 21.
- 30. A compound produced according to claim 25.
- 31. The method of claim 1, wherein the resultant polymer or oligomer ranges in molecular weight from about 1000 to about 200,00.
- 32. The method of claim 31, wherein the molecular weight more preferably ranges from about 5,000 to 50,000.
- 33. The method of claim 1, wherein the chain length of the resultant polymer or oligomer ranges from about 25 to 2500 angstroms.
- 34. The method of claim 33, wherein the chain length more preferably ranges from 250 to 1000 angstroms.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9400450-4 |
Feb 1994 |
SE |
|
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. Ser. No. 08/626,342 filed Apr. 12, 1996 which is incorporated by reference in its entirety herein. This application claims priority to PCT/SE95/00135, in turn, Application No. 9400450-4, filed Feb. 10, 1994.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09145267 |
Sep 1998 |
US |
Child |
09303656 |
May 1999 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09303656 |
May 1999 |
US |
Child |
09542993 |
Apr 2000 |
US |
Parent |
PCT/SE95/00135 |
Feb 1994 |
US |
Child |
08626342 |
Apr 1996 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08626342 |
Apr 1996 |
US |
Child |
09145267 |
Sep 1998 |
US |